BRVE (Braveheart Bio) Total Liabilities: $155.22 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BRVE Braveheart Bio Inc BRVE
8 GF Score
Price $31.93
View Full Analysis

What is Braveheart Bio Total Liabilities?

Braveheart Bio BRVE -2.72% 8 Total Liabilities is $155.22 Mil as of Dec. 2025. GuruFocus rates BRVE with a GF Score™ of 8/100.

Braveheart Bio's Total Liabilities for the quarter that ended in Dec. 2025 was $155.22 Mil.

Braveheart Bio's quarterly Total Liabilities stayed the same from . 20 ($0.00 Mil) to . 20 ($0.00 Mil) but then increased from . 20 ($0.00 Mil) to Dec. 2025 ($155.22 Mil).

Braveheart Bio's annual Total Liabilities stayed the same from . 20 ($0.00 Mil) to . 20 ($0.00 Mil) but then increased from . 20 ($0.00 Mil) to Dec. 2025 ($155.22 Mil).

Braveheart Bio Total Liabilities Historical Data

* Premium members only.

The historical data trend for Braveheart Bio's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Braveheart Bio Total Liabilities Chart

Braveheart Bio Annual Data
Trend Dec25
Total Liabilities
155.22

Braveheart Bio Semi-Annual Data
Dec25
Total Liabilities 155.22
BRVE
8GF Score
Braveheart Bio Inc BRVE
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Braveheart Bio Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Braveheart Bio's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5.242+(0+149.98
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=155.22

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=89.35--65.872
=155.22

Braveheart Bio's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5.242+(0+149.98
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=155.22

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=89.35--65.872
=155.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $155.22 Mil mean?
Braveheart Bio (BRVE) has a Total Liabilities of $155.22 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Braveheart Bio and its competitors.
Is Braveheart Bio's Total Liabilities too high?
Braveheart Bio's current Total Liabilities is $155.22 Mil. Overall, Braveheart Bio has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Braveheart Bio's Total Liabilities compare to ?
Braveheart Bio's Total Liabilities of $155.22 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Braveheart Bio and its competitors. Braveheart Bio's current Total Liabilities is $155.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Braveheart Bio stock overvalued right now?
Braveheart Bio (BRVE) has a current Total Liabilities of $155.22 Mil. The current Total Liabilities is $155.22 Mil. Braveheart Bio's overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Braveheart Bio (BRVE), the current Total Liabilities is $155.22 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Braveheart Bio Business Description

Comparable Companies
Address One Letterman Drive, Suite A4-300, Building A, San Francisco, CA, USA, 94129
Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).
8GF Score

Get the complete analysis for BRVE

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.93
Price